Benzinga's Top #PreMarket Gainers

shares surged 21.03 percent to $6.10 in pre-market trading after the company reported positive interim results from a Phase 2 clinical study of Cabaletta in oculopharyngeal muscular dystrophy.

shares rose 11.23 percent to $45.75 in pre-market trading after the company reported stronger-than-expected results for its third quarter.

shares rose 8.78 percent to $25.65 in pre-market trading after the company reported better-than-expected earnings for the third quarter.

shares climbed 7.43 percent to $8.10 in pre-market trading after the company reported that it has signed a new brand partner ALDO Group.

gained 4.47 percent to $25.02 in pre-market trading after the company reported upbeat results for the third quarter.